New combo therapy tackles tough tumors
NCT ID NCT04840394
First seen Nov 12, 2025 · Last updated May 24, 2026 · Updated 28 times
Summary
This early-phase trial tested a new drug called BDB001, alone or with another drug (pembrolizumab), in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. Only one person took part, so results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Florida Cancer Specialists
Sarasota, Florida, 34230, United States
-
START
San Antonio, Texas, 78229, United States
-
START MidWest
Grand Rapids, Michigan, 49501, United States
Conditions
Explore the condition pages connected to this study.